Recursion Pharmaceuticals remains a Hold amid competitive risks and delayed pipeline revenue.

Recursion Pharmaceuticals is rated as a Hold due to ongoing competitive risks and the fact that it is still several years away from generating significant revenue from its drug pipeline. While its AI-driven Recursion OS platform shows promise, it has yet to prove a clear advantage over well-funded competitors. The company faces challenges such as share dilution and increasing cash burn, with at least 18-24 months before potential pipeline revenue and likely additional capital raises. Investors should focus on near-term partnership revenue, milestone payments, and clinical progress, especially for the drug REC-4881, as the company reports earnings on May 5.